<DOC>
	<DOC>NCT01408576</DOC>
	<brief_summary>The primary objective of the study is assess the safety and tolerability of long-term epratuzumab treatment in subjects with Systemic Lupus Erythematosus (SLE)</brief_summary>
	<brief_title>Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Treatment period was extended by 2 years to a total of 4 years and an amendment was prepared accordingly.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Subject has completed the doubleblind study SL0009 (NCT01262365) or SL0010 (NCT01261793) or terminated prematurely at Week 16 or later in SL0009 or SL0010 due to lack of efficacy and would, in the opinion of the investigator, continue to benefit from continued epratuzumab treatment Subject has completed openlabel study SL0006 (NCT00383513) or SL0008 (NCT00660881), and would, in the opinion of the investigator, continue to benefit from continued epratuzumab treatment Women of childbearing potential must agree to use an acceptable method of birth control Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring British Isles Lupus Assessment Group Index (BILAG) level A disease Subjects with active, severe SLE disease activity which involves the renal system Subjects with concurrent relevant medical conditions like defined chronic infections or high risk of new significant infections Substance abuse or dependence History of malignant cancer Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>B-Cell immunotherapy</keyword>
	<keyword>Epratuzumab</keyword>
</DOC>